NHS approval to Genedrive for baby deafness trial test

NHS approval to Genedrive for baby deafness trial test

Genedrive a molecular diagnostics firm has obtained approval from the NHS Health Research Authority and ethics committee for the usage of the Antibiotic Induced Hearing (AIHL) test in hospitals trials.

This is happened to be the first ethical approval for a point-of-care genetic test relating to neonatal management in an acute setting.

The AIHL test will be studied in the PALOH study, including around 1,000 patients from two intensive care units in the UK. The study will commence from next month and will be carried out for approximately six months.

MT-RNR1 screening assay was designed by Genedrive for individuals with the m.1555A>G genotype. Statistics demonstrated that the genotype occurs in one out of 500 people.

The primary objective of the PALOH study will be to show the benefit of integrating Genedrive MT-RNR1 test platform into the neonatal emergency admissions process which already exists.

The lucky chance to bring the power of molecular testing in a point-of-care acute setting will undoubtedly majorly improve the lives of patients both in this trial and in future adoption of MT-RNR1 testing.

Performance of the AIHL test can be done on the genedrive molecular platform and is said to deliver results within 30 minutes